Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX) Stock Overview
Explore Neoleukin Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.2M
P/E Ratio
-0.65
EPS (TTM)
$-12.28
ROE
-0.40%
NLTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Neoleukin Therapeutics, Inc. (NLTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.65 and a market capitalization of 8.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.